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Abstract
This position statement describes the recommendations of the Clinical
Oncology Society of Australia (COSA) regarding management of cancerrelated malnutrition and sarcopenia. A multidisciplinary working group completed a review of the literature, focused on evidence-based guidelines, systematic reviews and meta-analyses, to develop recommendations for the
position statement. National consultation of the position statement content
was undertaken through COSA members. All people with cancer should be
screened for malnutrition and sarcopenia in all health settings at diagnosis
and as the clinical situation changes throughout treatment and recovery. People identified as “at risk” of malnutrition or with a high-risk cancer diagnosis
or treatment plan should have a comprehensive nutrition assessment; people
identified as “at risk” of sarcopenia should have a comprehensive evaluation
of muscle status using a combination of assessments for muscle mass, muscle
strength and function. All people with cancer-related malnutrition and sarcopenia should have access to the core components of treatment, including
medical nutrition therapy, targeted exercise prescription and physical and
psychological symptom management. Treatment for cancer-related malnutrition and sarcopenia should be individualised, in collaboration with the multidisciplinary team (MDT), and tailored to meet needs at each stage of cancer
treatment. Health services should ensure a broad range of health care professionals across the MDT have the skills and confidence to recognise malnutrition and sarcopenia to facilitate timely referrals and treatment. The position
statement is expected to provide guidance at a national level to improve the
multidisciplinary management of cancer-related malnutrition and
sarcopenia.
KEYWORDS
cancer, exercise, malnutrition, nutrition, sarcopenia

1 | B ACKGROUND
Malnutrition is characterised by loss of weight, loss of
muscle and loss of subcutaneous body fat.1 Cancer-related
malnutrition can occur due to the presence of the cancer
itself, the effect of cancer treatment on the consumption
or absorption of nutrients, or patients undertaking
“restrictive” cancer diets.2 Research over several decades
has shown cancer-related malnutrition is associated with
serious adverse consequences, including reduced survival
and ability to complete treatment, poorer quality of life
and higher costs to the health care system.3-7 It is a common condition, occurring in 30% to 40% of people with
cancer, yet it is under-recognised and under-treated.7
Australian studies have found that almost 50% of people
with cancer-related malnutrition are not under the care of
a dietitian.8 Malnutrition can occur in people with any

cancer diagnosis, although certain cancers, including head
and neck, gastrointestinal and lung cancers, have up to a
4-fold increased risk of malnutrition compared to breast
cancer.9 Malnutrition can occur in people of any body
mass index (BMI) category, including those classified as
overweight or obese.10,11 However, with the rising incidence of obesity in Australia the identification of malnutrition and underlying muscle loss is becoming more
complex and concurrently under-diagnosis is likely to rise.
Sarcopenia is characterised by loss of skeletal muscle
mass and strength with an impact on physical performance, and is a key component of cancer-related malnutrition.12,13 This is reflected in recent international
definitions of malnutrition where the assessment of muscle mass is a criterion for the diagnosis of malnutrition.14,15 Sarcopenia associated with ageing is known as
primary sarcopenia, as opposed to secondary sarcopenia
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which is associated with disease (including cancer), sedentary lifestyle or inadequate nutrition.12 Research in
cancer-related sarcopenia has largely focused on the
presence of low muscle mass rather than the presence of
both low muscle mass and low muscle function
(strength or performance).16-18 Similar to malnutrition,
low muscle mass can occur across all BMI categories.16
Cancer-related sarcopenia is associated with similar
adverse consequences to cancer-related malnutrition
and is also a common condition occurring in up to 60%
of people with cancer, depending on cancer type.18-20
Furthermore, sarcopenic obesity, a unique phenotype
where low muscle mass and obesity occur simultaneously, is independently associated with reduced survival and increased complications in multiple cancer
diagnoses and treatment modalities.21
Loss of muscle mass in cancer-related malnutrition
and sarcopenia may simply be related to reduced nutritional intake.2 Alternatively, muscle loss may develop as
a result of tumour-related metabolic alterations or the
presence of systemic inflammation.2 This is particularly
evident in cancer cachexia, a multifactorial syndrome
with a complex underlying pathology.22 While there are
similarities across these conditions, it is generally
accepted that weight and muscle loss occurring in cancer
cachexia cannot be reversed by conventional nutrition
intervention.23
Evidence from national and international guidelines
strongly supports the identification and treatment of
cancer-related malnutrition and sarcopenia prior to, during and post-treatment in order to improve outcomes for
people with cancer.3,6,24,25 Despite this, considerable variation in screening, diagnosis and intervention occurs
across Australian health care settings. Barriers to improving care largely include inadequate time and services and
varying perception of responsibility for identification and
treatment.26 Nevertheless, international studies demonstrate failure to improve care has a considerable financial
burden that is likely to translate to a similar impact on
the Australian health care system.27,28
This document outlines the position of Clinical
Oncology Society of Australia (COSA) on the role of
health professionals and health services in recognising
and treating patients with cancer-related malnutrition
and sarcopenia, with a focus on practice tips to support
implementation of optimal management. It is intended
for use by clinicians and health services to advocate for
the resources and services required to support optimal
management of cancer-related malnutrition and sarcopenia. Malnutrition and muscle loss also occur in adolescents and young adults with cancer, however this
document is intended to address the management of
these conditions in adults.
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2 | METHODS
A multidisciplinary expert working group of dietitians,
exercise physiologists, nurses, medical oncologists and
general practitioners was convened to develop the position
statement. A comprehensive literature review of PubMed
and Conchrane databases from 1 July 2013 to 3 June 2019
was undertaken by the working group using search terms
from the European Society of Clinical Nutrition and
Metabolism (ESPEN) guidelines on nutrition in cancer
patients.3 This was to capture literature not included in
the ESPEN guidelines, for which the literature search was
conducted up to 30 June 2013. A focus was placed on
using evidence-based guidelines, systematic reviews and
meta-analyses identified from the literature search to
inform the recommendations. Consensus of the working
group was used where evidence was limited. Subsequent
national consultation was undertaken with COSA members and key stakeholders, with relevant feedback incorporated into the position statement.

3 | RECOMMENDATIONS
Table 1 summarises COSA's position on cancer-related
malnutrition and sarcopenia. Table 2 contains suggestions for the implementation of recommendations into
health services. A pathway for the management of
cancer-related malnutrition and sarcopenia, applicable
across all health settings, is outlined in Figure 1.

3.1 | Identifying cancer-related
malnutrition and sarcopenia
1. All people with cancer should be screened for malnutrition in all health settings at diagnosis and repeated
as the clinical situation changes, using a screening
tool that is valid and reliable in the setting in which it
is intended for use.
2. All people with cancer should be screened for sarcopenia at diagnosis and repeated as the clinical situation changes, using the validated screening tool
SARC-F or SARC-F in combination with calf
circumference.
Cancer-related malnutrition and sarcopenia are
under-recognised and therefore under-treated conditions. Neither malnutrition nor sarcopenia should be
associated exclusively with being underweight, as these
conditions can be present at any body weight or BMI category including obesity.18,29 Timely and accurate identification of malnutrition and sarcopenia in all clinical
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T A B L E 1 Clinical Oncology Society of Australia position on
cancer-related malnutrition and sarcopenia
All people with cancer should be screened for malnutrition and
sarcopenia in all health settings at diagnosis and as the
clinical situation changes throughout treatment and recovery.
All people with cancer identified as being “at risk” of
malnutrition following screening or with a cancer diagnosis
or treatment plan known to lead to high risk of malnutrition
should have comprehensive nutrition assessment using a tool
validated in the oncology population.
All people with cancer identified as being “at risk” of
sarcopenia following appropriate screening should have a
comprehensive evaluation of muscle status using a
combination of assessments for muscle mass, muscle strength
and function.
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TABLE 2

Tips for implementing recommendations into

practice
Identification
Consider incorporating screening for malnutrition and
sarcopenia into existing multidisciplinary and/or supportive
care screening processes or patient-reported outcomes to aid
ease of completion and compliance, reduce the need for
additional resources and to support the initiation of
appropriate assessment and care.
Screening should focus on early identification using a
systematised model of care or pathway that defines the tools
to be used, who will conduct screening, the timing and
frequency of screening, and pathways for treatment referrals
appropriate to the setting.
Assessment

All people with cancer-related malnutrition and sarcopenia
should have access to the core components of treatment
including medical nutrition therapy, targeted exercise
prescription and physical activity advice, and physical and
psychological symptom management.

Malnutrition assessment should be incorporated into the
appropriate nutrition care policy directives with local
governance, management committees and performance
review processes embedded to support successful and
sustainable implementation.

Treatment for cancer-related malnutrition and sarcopenia
should be individualised, in collaboration with the
multidisciplinary team (MDT), and tailored to meet needs at
each stage of cancer treatment.

A measure of muscle mass should be a component of
assessment of malnutrition and sarcopenia and incorporated
into routine clinical practice.

Health services should ensure a broad range of health care
professionals across the MDT have the skills and confidence
to recognise malnutrition and sarcopenia to facilitate timely
referrals and treatment.

practice settings is essential to support the initiation of
optimal multidisciplinary care for people with these conditions, and a subsequent reduction in disability, mortality and health care costs.3,7,30 This identification process,
commonly known as screening, enables recognition of
people with cancer as “at risk” or “not at risk” of these
conditions.
Screening for malnutrition should be undertaken on
all people with cancer at diagnosis, and repeated as clinically indicated throughout each modality of treatment
(eg, surgery, radiation therapy, chemotherapy), posttreatment and surveillance.3,24,25 Where limited resources
restrict the ability to screen all patients, resources should
be devoted to ensuring those at highest risk are screened
(Table 3). Malnutrition screening should be undertaken
using a malnutrition screening tool validated in the setting in which it is intended for use.6,24 A number of malnutrition screening tools have been shown to be valid
and reliable for identifying malnutrition in people with
cancer including the Malnutrition Screening Tool
(MST), Malnutrition Universal Screening Tool (MUST),
Malnutrition Screening Tool for Cancer Patients
(MSTC) and the Patient-Generated Subjective Global
Assessment Short Form (PG-SGA SF).3 The MST and

Identification of barriers and enablers to malnutrition and
sarcopenia assessment at individual, team and system levels is
the first step to facilitate adherence to evidence-based
nutrition care recommendations and policies.
Treatment
Models of care to treat malnutrition and sarcopenia should
provide consistent information regarding cancer-related
malnutrition and sarcopenia across disciplines and
throughout phases of treatment to ensure reinforcement of a
clear treatment plan.
Consider the use of a care pathway, or similar process,
developed by MDT members and people with cancer to
support implementation of optimal care for cancer-related
malnutrition and sarcopenia.
Multidisciplinary care
Engage consumers in the development and evaluation of MDT
services across the continuum of care.
Utilise a framework, for example team mental model, to
develop and refine MDT services to optimise the success of
the team, and importantly clinical and patient-reported
outcome and experience measures.

MUST are most commonly used in Australia and can be
self-administered or completed by any health professional.31,32 Screening for malnutrition can be bypassed
for people with a cancer diagnosis or treatment plan
known to lead to high risk of malnutrition, for example,
radiation therapy with or without chemotherapy to
the gastrointestinal tract or head and neck area.6,25
All people with cancer identified as being “at risk” of
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FIGURE 1

Pathway for the management of cancer-related malnutrition and sarcopenia within acute, community and primary care

health services

TABLE 3

Factors indicative of high risk of malnutrition in people with cancer

Cancer diagnosis

Treatment

Other

Head and neck

Radiation therapy to oral cavity or gastrointestinal tract

Advanced stage disease

Upper or lower gastrointestinal

Chemotherapy, immunotherapy or targeted therapy
with risk of gastrointestinal toxicity

Older age (>65 years)

Thoracic

Stem cell transplant

Acute leukaemia (myeloid and
lymphoid)

Surgery to the oral cavity or gastrointestinal tract
Steroid use with treatment

malnutrition following screening, or with a diagnosis or
treatment plan that places them at high risk of malnutrition, should be referred to an accredited practising
dietitian for a comprehensive nutritional assessment
and initiation of appropriate treatment.3,6,24
Screening for sarcopenia should be completed in all
people with cancer at diagnosis and as clinically indicated throughout each modality of treatment (eg, surgery, radiation therapy, chemotherapy), post-treatment
and surveillance. The SARC-F is a sarcopenia screening
tool that has been well studied and validated in older

adults.33 The SARC-F has recently been validated for
use in people with cancer, either alone or in combination with measurement of calf circumference for greater
sensitivity.34 All people identified as “at risk” of sarcopenia should be referred to an accredited practising
dietitian and exercise specialist that is, accredited exercise physiologist and/or physiotherapist, experienced in
the cancer setting and with knowledge of body composition science, for assessment of muscle strength, muscle
mass and physical performance and initiation of appropriate treatment.

KISS ET AL.

3.2 | Assessing cancer-related
malnutrition and sarcopenia
1. All people with cancer identified as being “at risk” of
malnutrition following screening or with a cancer
diagnosis or treatment plan known to lead to high risk
of malnutrition should have a comprehensive nutrition assessment using a tool validated in the oncology
population.
2. All people with cancer identified as being “at risk” of
sarcopenia following appropriate screening should
have a comprehensive evaluation of muscle status
using a combination of assessments for muscle mass,
muscle strength and function.
3. Interpretation of diagnostic criteria for sarcopenia
should be applied recognising that:
a. Threshold values for assessing muscle mass, muscle strength and physical performance are variable.
b. Care should be taken to determine the appropriate
cut-off values in the population in which they are
being applied.
c. Most data regarding muscle strength and performance comes from older populations.
d. The applicability of diagnostic criteria in different
ethnicities is uncertain.
Nutrition assessment is recommended for all people
with cancer identified as “at risk” of malnutrition following screening or with a cancer diagnosis or treatment
plan known to lead to high risk of malnutrition for example, patients receiving radiation therapy to the oral cavity
or gastrointestinal tract.6,25 Nutrition assessment and
malnutrition diagnosis should be completed by an appropriately trained health care professional such as an
accredited practising dietitian or if not available, other
allied health or medical professional. Nutrition assessment should be repeated as the clinical situation changes
and incorporated into routine clinical consultations.3
Nutrition assessment should incorporate measures of
involuntary weight loss, BMI, body composition, food
intake and nutrient absorption, functional status and
inflammation.3 The 2019 Global Leadership Initiative on
Malnutrition (GLIM) has produced a consensus statement outlining the recommended assessment domains
for a diagnosis of malnutrition including etiologic
(reduced food intake or assimilation; inflammation) and
phenotypic criteria (weight loss; low BMI; reduced muscle mass).15 The Patient-Generated Subjective Global
Assessment (PG-SGA)35 and Subjective Global Assessment (SGA)36 are validated assessment tools that align
with the GLIM criteria for diagnosing malnutrition and
can be used to assess and diagnose malnutrition in people
with cancer.6
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Sarcopenia assessment is recommended for all people
identified as “at risk” of sarcopenia following screening
and is ideally performed at the time of cancer diagnosis
and before an initial treatment plan is implemented.
Reassessment should occur as the clinical situation
changes and incorporated into routine clinical consultations during active treatment and then ongoing surveillance throughout the course of care. Sarcopenia
assessment and diagnosis should be completed by an
appropriately trained health care professional such as an
accredited practising dietitian, accredited exercise physiologist, physiotherapist or other allied health or medical professional. Assessment should consider whether it is primary
sarcopenia (age-related) or secondary sarcopenia (other
causal factors).13 These causal factors may include:
(a) Disease—secondary to a systemic disease especially
where inflammation is present as in cancer; (b) Inactivity—
sedentary lifestyle or disease-related immobility or disability; or (c) Malnutrition—as a result of inadequate energy or
protein caused by anorexia, malabsorption, food insecurity
or limited ability to eat.13
There is no global consensus on the diagnostic criteria
for sarcopenia. Commonly used definitions include the
European Working Group on Sarcopenia in Older People
(EWGSOP) 112 and EWGSOP 2,13 and the Foundation for
the National Institutes of Health (FNIH) Biomarkers Consortium Sarcopenia Project37 (Table 4). However, these
definitions and cut-points have been developed based on
research in older adults and have not been extensively
researched in cancer populations. Most research in cancer
has assessed sarcopenia based on low muscle mass alone
from computed tomography images using cut-points prognostic for poor survival.40,44 The various methods used for
diagnosing sarcopenia are presented in Table 4. Selection
of assessment method may depend on patient factors,
access to the required technical resources and the purpose
of testing. Clinicians and researchers should understand the strengths and limitations of the assessment
method being applied and understand these are not
interchangeable.12,13 Ongoing research will contribute
to identifying cut-points relative to patient population
and ethnicity.

3.3 | Treating cancer-related
malnutrition and sarcopenia
1. All people with cancer-related malnutrition and sarcopenia should have access to the core components of
treatment including individualised medical nutrition
therapy, targeted exercise prescription and physical
activity advice and physical and psychological symptom management.
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TABLE 4
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Appropriate methods for assessing sarcopenia12,38,39

Definition

Low muscle strength

Low muscle mass
a

2

Poor muscle function
2

EWGSOP 1 (2010)—Low
muscle mass + low muscle
strength or low physical
performance

Grip strength: <30 kg men;
<20 kg women

ALM /height (m) : <7.26 kg/m
men; <5.50 kg/m2 women

Gait speed:≤0.8 m/second (4 m
walk) or SPPB Score ≤8
points

FNIH (2014)—Low muscle
mass + low muscle strength

Grip strength: <26 kg men;
<16 kg women

ALM/BMI: <0.789 kg/BMI
men; <0.512 kg/BMI women

NA

EWGSOP 2 (2019)—Low
muscle strength + low
muscle mass or low physical
performance

Grip strength: <27 kg men;
<16 kg women or Chair
Stands: >15 seconds five rises

ALM/height (m)2: <7.00 kg/m2
men; <5.50 kg/m2 women or
ALM: <20 kg men; <15 kg
women

Gait speed: ≤0.8 m/second (4 m
walk) or SPPB Score ≤8
points or TUG ≥20 seconds
or 400 m walk ≥6 minutes or
non-completion. Only used to
classify severity of sarcopenia.

Cancer-specific CT image
analysis researchb—Low
muscle mass

NA

SMI (SMA/height [m]2) at L3:
<52.4 cm2/m2 (men)18;
<38.5 cm2/m2 (women)18; or
<43 cm2/m2 (men with
BMI < 24.9)40; <53 cm2/m2
(men with BMI ≥ 25)40;
<41 cm2/m2 (women of any
BMI)40

NA

Notes: Muscle mass outputs produced automatically by BIA and BIS devices may be less accurate due potential to be affected by fluid shifts
and a lack of transparency regarding the population-specific regression equations underpinning their outputs owing to their proprietary
nature39,41-43; however, some guidelines support use in clinical practice.
Abbreviations: ALM, appendicular lean mass; BMI, body mass index; CT, computed tomography; EWGSOP 1, European Working Group on
Sarcopenia in Older People; EWGSOP 2, European Working Group on Sarcopenia in Older People updated definition; FNIH, Foundation for
the National Institutes of Health Biomarkers Consortium Sarcopenia Project; SMA, skeletal muscle area determined from cross-sectional CT
image at the third lumbar vertebrae; SMI, Skeletal Muscle Index; SPPB, short physical performance battery; TUG, timed up and go.13
a
ALM can be assessed using dual energy X-ray absorptiometry (DXA), magnetic resonance imaging (MRI), CT, raw bioelectrical impedance
analysis (BIA) or bioelectrical impedance spectroscopy (BIS).
b
Multiple cut-points for SMI at the third lumbar vertebrae are used in the literature, depending on population and ethnicity. These are
suggested cut-points; however, clinicians are advised to research the most appropriate cut-point for their population.

2. Treatment for cancer-related malnutrition and sarcopenia should be individualised, in collaboration
with the multidisciplinary team (MDT), and tailored
to consider multi-morbidities and meet needs at each
stage of cancer treatment.
Treatment of cancer-related malnutrition and sarcopenia aims to provide adequate nutritional intake and
participation in exercise in order to optimise body composition with a focus on preserving or improving lean
mass and physical function, as well as assisting patients
to complete cancer treatment.6,25,29 However, people
with cancer commonly report unmet needs in regards to
access and provision of nutrition and exercise advice for
the management of their malnutrition or sarcopenia,
and are seeking consistent care from health professionals across their treating team to address these
needs.45-48
Medical nutrition therapy that considers symptoms,
social situation and treatment plan, has been found to

improve nutritional intake, weight and patient-reported
physical function and reduce treatment breaks and
unplanned hospital admissions.3,6,25 Sufficient nutritional
intake of energy and protein is required to treat malnutrition, with evidence-based guidelines recommending
between 105 and 125 kJ/kg/day and between 1.0 and 1.5 g/
kg/day in protein.3 Preliminary data suggest that in fact a
higher protein intake of 2.0 g/kg/day may be required to
combat muscle loss; however, this is not yet supported by
sufficient research.17 Specific recommendations regarding
the use and timing of initiation of medical nutrition therapy, including enteral and parenteral nutrition, and
Enhanced Recovery After Surgery protocols are available
for some cancer types including head and neck and upper
and lower gastrointestinal cancers.3,6,24,25
For medical nutrition therapy to be optimally effective, it needs to occur alongside exercise intervention.49
Exercise training provides the necessary support for
nutrition intervention to improve (or prevent worsening)
in body composition, specifically, preservation or
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increases in lean tissue, with or without changes in body
weight.3,50,51 Resistance exercise is more effective than
aerobic exercise at improving muscle mass and
strength.52 However, aerobic exercise remains relevant as
it also modulates muscle metabolism, insulin sensitivity
and levels of inflammation in a way that could potentially aid in preservation of muscle mass and function.52
As such, in line with the most up to date Australian exercise prescription guidelines for people with cancer, individually prescribed multimodal exercise training
(including targeted aerobic and resistance exercise) at
moderate to high intensity, with emphasis on resistance
exercise incorporating exercises for major muscle groups,
is recommended.52
Although promising, evidence is variable for the use
of anabolic or appetite stimulating agents, such as progestins, or non-steroidal anti-inflammatory agents, and their
use should be evaluated on an individual basis by the
MDT or disease protocol.3 Supportive care screening to
identify unmet needs, including symptom management
and psychosocial needs, is important for a holistic
approach.
Interventions are most effective when commenced
early, with a focus on prevention or the treatment of
mild to moderate malnutrition and/or sarcopenia.22
However, despite the evidence for treatment of cancerrelated malnutrition and sarcopenia, consistent and
equitable access to care is lacking.3,47,48 The potential
benefit to the health system through implementing
evidence-based treatment of malnutrition and sarcopenia is significant, estimated to be the equivalent of
AU$800 000 per 100 000 population.27,53 Detailed recommendations regarding evidence-based treatment for
people undergoing different treatment modalities and
for specific cancer diagnoses can be found in the relevant evidence-based guidelines.3,6,24,25,52

3.4 | Role of the multidisciplinary team
1. Health services should ensure a broad range of health
care professionals across the MDT have the skills and
confidence to recognise malnutrition and sarcopenia
to facilitate timely referrals and treatment.
2. MDTs should work towards an individualised and
coordinated approach to treating cancer-related malnutrition and sarcopenia.
A multidisciplinary approach to identifying and treating
cancer-related malnutrition and sarcopenia is essential.
Alongside medical nutrition therapy, interventions that
have been shown to contribute to optimising nutritional status and body composition include exercise, management of
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treatment side effects through optimising medications and
the management of anorexia and dysphagia.3,25 Frameworks, such as the team mental model, have been found to
optimise team processes and functioning.54 Multidisciplinary cancer prehabilitation and rehabilitation programs providing individualised care demonstrate capacity
to improve nutritional status, muscle mass and strength,
fatigue and performance status.55-58 These interventions
require the specialist skills of various MDT members as part
of a coordinated approach to individualised treatment of
cancer-related malnutrition and sarcopenia and can be
accessed through acute hospital services, community-based
services or general practices.
Guidance regarding optimal practice at a national
level is expected to improve the management of cancerrelated malnutrition and sarcopenia across health sectors.
Implementation of the position statement recommendations within health services will require the support and
training of multidisciplinary health professionals, health
service managers and policy makers. The position statement recommendations and pathway provide a framework for achieving optimal care.
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